Literature DB >> 31644440

Precision medicine and treatable traits in chronic airway diseases - where do we stand?

Charlotte Suppli Ulrik1,2, Susanne Vijverberg3,4, Nicola A Hanania5, Zuzana Diamant6,7,8.   

Abstract

PURPOSE OF REVIEW: To provide an update on the implementation of precision medicine, based on treatable traits and mechanisms, in the daily clinical management of chronic airways diseases. RECENT
FINDINGS: Recent insights into the complex and heterogeneous nature of chronic airway diseases including chronic obstructive pulmonary disease (COPD) and asthma identified several clinical and inflammatory phenotypes. This shifted the management focus of these diseases away from the prototypic disease labels and paved the way for developing novel targeted therapies.The concept of precision medicine aims to link the right patient to the right treatment, while minimizing the risk of adverse effects. Several treatable features ('treatable traits') have now been identified for these chronic airway diseases, including pulmonary, extra-pulmonary, and psychological/lifestyle/environmental traits. As the next step, innovative detection techniques should clarify underlying mechanisms and molecular pathways of these treatable traits and novel reliable point-of-care (composite) biomarkers to help predict responders to targeted therapies must be developed.
SUMMARY: Precision medicine links the right patient to the right treatment. Identification of treatable traits in asthma and COPD will help optimize the treatment approach in these heterogeneous diseases. Furthermore, in-depth identification of underlying molecular pathways and reliable biomarkers in chronic airways diseases to guide targeted treatment in individual patients is in progress.

Entities:  

Mesh:

Year:  2020        PMID: 31644440     DOI: 10.1097/MCP.0000000000000639

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  4 in total

1.  Treatable Mechanisms in Asthma.

Authors:  Mario Cazzola; Josuel Ora; Francesco Cavalli; Paola Rogliani; Maria Gabriella Matera
Journal:  Mol Diagn Ther       Date:  2021-02-11       Impact factor: 4.074

2.  The Relation Between Clinical Phenotypes, GOLD Groups/Stages and Mortality in COPD Patients - A Prospective Multicenter Study.

Authors:  Kristian Brat; Michal Svoboda; Jaromir Zatloukal; Marek Plutinsky; Eva Volakova; Patrice Popelkova; Barbora Novotna; Tomas Dvorak; Vladimir Koblizek
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-04-28

3.  Association of Systemic Inflammation with Depressive Symptoms in Individuals with COPD.

Authors:  Hilary C Strollo; Seyed M Nouraie; Karin F Hoth; Craig M Riley; Chad Karoleski; Yingze Zhang; Nicola A Hanania; Russell P Bowler; Jessica Bon; Frank C Sciurba
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-09-03

4.  Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients.

Authors:  Anders Løkke; Ole Hilberg; Peter Lange; Rikke Ibsen; Georgios Stratelis; Sofie de Fine Licht; Jesper Lykkegaard
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-03-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.